Annual report pursuant to Section 13 and 15(d)

Note 1 - Description of Business and Summary of Significant Accounting Policies

v3.7.0.1
Note 1 - Description of Business and Summary of Significant Accounting Policies
12 Months Ended
Jun. 30, 2017
Notes to Financial Statements  
Business Description and Accounting Policies [Text Block]
Note
1.
 Description of Business and Summary of Significant Accounting Policies:
 
Description of business:
Bio-Techne Corporation and subsidiaries, collectively doing business as Bio-Techne (the Company), develop, manufacture and sell biotechnology and clinical diagnostic products worldwide. With its deep product portfolio and application expertise, Bio-Techne is a leader in providing specialized proteins, including cytokines and growth factors, and related immunoassays, small molecules and other reagents to the research and diagnostics markets.
 
Use of estimates:
The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include the valuation of accounts receivable, available-for-sale investments, inventory, intangible assets, contingent consideration, stock based compensation and income taxes. Actual results could differ from these estimates.
 
Principles of consolidation:
The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated.
 
Translation of foreign financial statements:
Assets and liabilities of the Company's foreign operations are translated at year-end rates of exchange and the resulting gains and losses arising from the translation of net assets located outside the U.S. are recorded as other comprehensive income (loss) on the consolidated statements of earnings and comprehensive income. The cumulative translation adjustment is a component of accumulated other comprehensive loss on the consolidated balance sheets. Foreign statements of earnings are translated at the average rate of exchange for the year. Foreign currency transaction gains and losses are included in other non-operating expense in the consolidated statements of earnings and comprehensive income.
 
 
Revenue recognition:
The Company recognizes revenue when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Payment terms for shipments to end-users are generally net
30
days. Payment terms for distributor shipments
may
range from
30
to
90
days. Freight charges billed to end-users are included in net sales and freight costs are included in cost of sales. Freight charges on shipments to distributors are paid directly by the distributor. Any claims for credit or return of goods must be made within
10
days of receipt. Revenues are reduced to reflect estimated credits and returns. Sales, use, value-added and other excise taxes are
not
included in revenue.
 
Research and development:
Research and development expenditures are expensed as incurred. Development activities generally relate to creating new products, improving or creating variations of existing products, or modifying existing products to meet new applications.
 
Advertising costs:
Advertising expenses (including production and communication costs) were
$4.5
million
$5.2
million, and
$4.1
million for fiscal
2017,
2016,
and
2015
respectively. The Company expenses advertising expenses as incurred.
  
Income taxes:
The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized to record the income tax effect of temporary differences between the tax basis and financial reporting basis of assets and liabilities. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Tax positions taken or expected to be taken in a tax return are recognized in the financial statements when it is more likely than
not
that the position would be sustained upon examination by tax authorities. A recognized tax position is then measured at the largest amount of benefit that is greater than
fifty
percent likely of being realized upon ultimate settlement. The Company recognizes interest and penalties related to unrecognized tax benefits in income tax expense.
 
See Note
10
for additional information regarding income taxes.
 
Comprehensive income:
Comprehensive income includes charges and credits to shareholders' equity that are
not
the result of transactions with shareholders. Our total comprehensive income consists of net income, unrealized gains and losses on available-for-sale marketable securities, and foreign currency translation adjustments. The items of comprehensive income, with the exception of net income, are included in accumulated other comprehensive loss in the consolidated balance sheets and statements of shareholders' equity.
 
Cash and cash equivalents:
Cash and cash equivalents include cash on hand and highly-liquid investments with original maturities of
three
months or less.
 
Available-for-sale investments:
Available-for-sale investments consist of debt instruments with original maturities of generally
three
months to
three
years and equity securities. Available-for-sale investments are recorded based on trade-date. The Company considers all of its marketable securities available-for-sale and reports them at fair value.
Unrealized gains and losses on available-for-sale securities are excluded from income, but are included, net of taxes, in other comprehensive income. If an "other-than-temporary" impairment is determined to exist, the difference between the value of the investment security recorded in the financial statements and the Company's current estimate of the fair value is recognized as a charge to earnings in the period in which the impairment is determined.
 
Trade accounts receivable:
Trade accounts receivable are initially recorded at the invoiced amount upon the sale of goods or services to customers, and they do
not
bear interest. They are stated net of allowances for doubtful accounts, which represent estimated losses resulting from the inability of customers to make the required payments. When determining the allowances for doubtful accounts, we take several factors into consideration, including the overall composition of accounts receivable aging, our prior history of accounts receivable write-offs, the type of customer and our day-to-day knowledge of specific customers. Changes in the allowances for doubtful accounts are included in selling, general and administrative (SG&A) expense in our consolidated statements of earnings and comprehensive income. The point at which uncollected accounts are written off varies by type of customer.
 
Inventories:
Inventories are stated at the lower of cost (
first
-in,
first
-out method) or market. The Company regularly reviews inventory on hand for slow-moving and obsolete inventory, inventory
not
meeting quality control standards and inventory subject to expiration. To meet strict customer quality standards, the Company has established a highly controlled manufacturing process for proteins, antibodies and its chemically-based products. These products require the initial manufacture of multiple batches to determine if quality standards can be consistently met. In addition, the Company will produce larger batches of established products than current sales requirements due to economies of scale. The manufacturing process for these products, therefore, has and will continue to produce quantities in excess of forecasted usage. The Company values its manufactured protein and antibody inventory based on a
two
-year forecast and its chemically-based products on a
five
-year forecast. Inventory quantities in excess of the forecast are
not
valued due to uncertainty over salability. 
 
The company records a lower of cost or market adjustment to cost of sales for those quantities that are in excess of the manufactured protein and antibody
two
-year forecast and the chemically-based products
five
year forecast. For the years ended
June 30, 2017,
2016,
and
2015
the amount recognized in net sales of inventory sold that was
not
valued is
not
material
.
 
Property and equipment:
Property and equipment are recorded at cost. Equipment is depreciated using the straight-line method over an estimated useful life of
five
years. Buildings, building improvements and leasehold improvements are amortized over estimated useful lives of
5
to
40
years. Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount
may
not
be recoverable. In the current year, the Company has identified
no
such events.
 
Intangibles assets:
Intangible assets are stated at historical cost less accumulated amortization. Amortization expense is generally determined on the straight-line basis over periods ranging from
1
year to
20
years. Each reporting period, we evaluate the remaining useful lives of our amortizable intangibles to determine whether events or circumstances warrant a revision to the remaining period of amortization. If our estimate of an asset's remaining useful life is revised, the remaining carrying amount of the asset is amortized prospectively over the revised remaining useful life. In the current year, the Company has identified
no
such events.
 
Impairment of long-lived assets and amortizable intangibles:
We evaluate the recoverability of property, plant, equipment and amortizable intangibles whenever events or changes in circumstances indicate that an asset's carrying amount
may
not
be recoverable. Such circumstances could include, but are
not
limited to, (
1
) a significant decrease in the market value of an asset, (
2
) a significant adverse change in the extent or manner in which an asset is used or in its physical condition, or (
3
) an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of an asset. We compare the carrying amount of the asset to the estimated undiscounted future cash flows associated with it. If the sum of the expected future net cash flows is less than the carrying value of the asset being evaluated, an impairment loss would be recognized. The impairment loss would be calculated as the amount by which the carrying value of the asset exceeds the fair value of the asset. As quoted market prices are
not
available for the majority of our assets, the estimate of fair value is based on various valuation techniques, including the discounted value of estimated future cash flows.
 
The evaluation of asset impairment requires us to make assumptions about future cash flows over the life of the asset
being evaluated. These assumptions require significant judgment and actual results
may
differ from assumed and estimated amounts.
No
triggering events were identified and
no
impairments were recorded for property, plant, and equipment or amortizable intangibles were recorded during fiscal year
2017.
 
Impairment of goodwill:
We evaluate the carrying value goodwill during the
fourth
quarter each year and between annual evaluations if events occur or circumstances change that would indicate a possible impairment. Such circumstances could include, but are
not
limited to, (
1
) a significant adverse change in legal factors or in business climate, (
2
) unanticipated competition, (
3
) an adverse action or assessment by a regulator, or (
4
) an adverse change in market conditions that are indicative of a decline in the fair value of the assets.
 
To analyze goodwill for impairment, we must assign our goodwill to individual reporting units. Identification of reporting units includes an analysis of the components that comprise each of our operating segments, which considers, among other things, the manner in which we operate our business and the availability of discrete financial information. Components of an operating segment are aggregated to form
one
reporting unit if the components have similar economic characteristics. We periodically review our reporting units to ensure that they continue to reflect the manner in which we operate our business.
 
2017
Goodwill Impairment Analysis
 
In completing our
2017
annual goodwill impairment analysis, we elected to perform a quantitative assessment for all of our reporting units. A quantitative assessment involves comparing the carrying value of the reporting unit, including goodwill, to its estimated fair value. Carrying value is based on the assets and liabilities associated with the operations of the reporting unit, which often requires the allocation of shared or corporate items among reporting units. In accordance with ASU
2017
-
04,
a goodwill impairment charge is recorded for the amount by which the carrying value of a reporting unit exceeds the fair value of the reporting unit. In determining the fair values of our reporting units, we utilized the income approach. The income approach is a valuation technique under which we estimated future cash flows using the reporting unit's financial forecast from the perspective of an unrelated market participant. Using historical trending and internal forecasting techniques, we projected revenue and applied our fixed and variable cost experience rates to the projected revenue to arrive at the future cash flows. A terminal value was then applied to the projected cash flow stream. Future estimated cash flows were discounted to their present value to calculate the estimated fair value. The discount rate used was the value-weighted average of our estimated cost of capital derived using both known and estimated customary market metrics. In determining the estimated fair value of a reporting unit, we were required to estimate a number of factors, including projected operating results, terminal growth rates, economic conditions, anticipated future cash flows, the discount rate and the allocation of shared or corporate items.
 
Because our
2017
quantitative analysis included all of our reporting units, the summation of our reporting units' fair values was compared to our consolidated fair value, as indicated by our market capitalization, to evaluate the reasonableness of our calculations.
 
The quantitative assessment completed as of
June 30, 2017
indicated that all of the reporting units had a substantial amount of headroom. This impairment assessment is sensitive to changes in forecasted cash flows, as well as our selected discount rate. Changes in the reporting unit's results, forecast assumptions and estimates could materially affect the estimation of the fair value of the reporting units.
 
2016
and
2015
Goodwill Impairment Analysis
 
The Company used a qualitative test for all reporting units during the
fourth
quarter for fiscal year
2016
and fiscal year
2015
with
one
exception. The company elected to utilize a quantitative test for the Protein Platforms reporting unit for fiscal year
2016
using the previously described income approach given that this is a newer reporting unit created primarily through acquisitions.
The qualitative analyses for our other reporting units completed during
2016
and
2015
evaluated factors including, but
not
limited to, economic, market and industry conditions, cost factors and the overall financial performance of the reporting units. In completing these assessments, we noted
no
changes in events or circumstances which indicated that it was more likely than
not
that the fair value of any reporting unit was less than its carrying amount. Based on the testing performed for the Protein Platforms reporting unit, fair value exceeded carrying value by a substantial amount and
no
adjustment to the carrying value of goodwill was necessary.
 
 
There has been
no
impairment of goodwill since the adoption of Financial Accounting Standards Board (“FASB”) ASC
350
guidance for goodwill and other intangibles on
July 1, 2002.
 
Investments in unconsolidated entities:
The Company periodically invests in the equity of start-up and early development stage companies. The accounting treatment of each investment (cost method or equity method) is dependent upon a number of factors, including, but
not
limited to, the Company's share in the equity of the investee and the Company's ability to exercise significant influence over the operating and financial policies of the investee.
 
Other Significant Accounting Policies
 
The following table includes a reference to additional significant accounting policies that are described in other notes to the financial statements, including the note number:
 
Policy
 
Note
 
Fair value measurements
   
4
 
Earnings per share
   
8
 
Share-based compensation
   
9
 
Reportable segments
   
11
 
 
Recently Adopted Accounting Pronouncements
 
In
April 2015,
the Financial Accounting Standards Board (“FASB”) issued ASU
No.
2015
-
05,
Customer's Accounting for Fees Paid in a Cloud Computing Arrangement
. The standard provides guidance to customers about whether a cloud computing arrangement includes a software license. If the arrangement does include a software license, the software license element of the arrangement should be accounted for in the same manner as the acquisition of other software licenses. We adopted this standard on
July 1, 2016,
applying it prospectively to all arrangements entered into or materially modified on or after
July 1, 2016.
Adoption of this standard did
not
have a significant impact on our results of operations or financial position.
 
In
September 2015,
the FASB issued ASU
No.
2015
-
16,
Simplifying the Accounting for Measurement-Period Adjustments.
When recording the purchase price allocation for a business combination in the financial statements, an acquirer
may
record preliminary amounts when measurements are incomplete as of the end of a reporting period. When the required information is received to finalize the purchase price allocation, the preliminary amounts are adjusted. These adjustments are referred to as measurement-period adjustments. This standard eliminates the requirement to restate prior period financial statements for measurement-period adjustments. Instead, it requires that the cumulative impact of a measurement-period adjustment be recognized in the reporting period in which the adjustment is identified. We adopted this standard on
July 1, 2016,
applying it prospectively. Application of this standard did
not
have a significant impact on our results of operations or financial position.
 
In
August 2016,
the FASB issued ASU
No.
2016
-
15,
Classification of Certain Cash Receipts and Cash Payments
. The standard is intended to reduce diversity in practice in how certain transactions are classified in the statement of cash flows. We elected to early adopt this standard as of
July 1, 2016.
As our consolidated statement of cash flows presentation was in compliance with the new guidance, adoption of this standard had
no
impact on our consolidated financial statements.
 
In
January 2017,
the FASB issued ASU
No.
2017
-
04,
Simplifying the Test for Goodwill Impairment
. The standard removes Step
2
of the goodwill impairment test, which requires a company to perform procedures to determine the fair value of a reporting unit's assets and liabilities following the procedure that would be required in determining the fair value of assets acquired and liabilities assumed in a business combination. Instead, a goodwill impairment charge will now be measured as the amount by which a reporting unit's carrying value exceeds its fair value,
not
to exceed the carrying amount of goodwill. We elected to early adopt this standard on
January 1, 2017.
As we have
not
been required to complete Step
2
of the goodwill impairment test, this standard did
not
have an impact on our consolidated financial statements.
 
Pronouncements Issued but
Not
Yet Adopted
 
In
May 2014,
the FASB issued ASU
No.
2014
-
09,
Revenue from Contracts with Customers
. The standard provides revenue recognition guidance for any entity that enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of non-financial assets, unless those contracts are within the scope of other accounting standards. The standard also expands the required financial statement disclosures regarding revenue recognition. The new guidance is effective for us on
July 1, 2018.
In addition, in
March 2016,
the FASB issued ASU
No.
2016
-
08,
Principal versus Agent Considerations (Reporting Revenue Gross versus Net)
, in
April 2016,
the FASB issued ASU
No.
2016
-
10,
Identifying Performance Obligations and Licensing,
and in
May 2016,
the FASB issued ASU
No.
2016
-
12,
Narrow-Scope Improvements and Practical
Expedients
. These standards are intended to clarify aspects of ASU
No.
2014
-
09
and are effective for us upon adoption of ASU
No.
2014
-
09.
The Company’s approach to implementing the new standard includes performing a detailed review of key contracts representative of its different businesses, and comparing historical accounting policies and practices to the new standard. In addition to expanded disclosures associated with the new standard, the Company is continuing to assess the impact on the Company’s consolidated financial statements. The guidance permits
two
methods of adoption, retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method).
We currently anticipate that we will adopt the standards using cumulative catch-up transition method.
 
In
July 2015,
the FASB issued ASU
2015
-
11,
Simplifying the Measurement of Inventory
. This provision would require inventory that was previously recorded using
first
-in,
first
-out (“FIFO”) to be recorded at lower of cost or net realizable value. Net realizable value is the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This guidance is effective for fiscal years beginning after
December 15, 2016
and interim periods within those years, which for us will be
July 1, 2017.
The amendments in this guidance should be applied prospectively with earlier application permitted as of the beginning of an interim or annual period. The Company does
not
expect the updated guidance to have a significant impact on future financial statements.
 
In
January 2016,
the FASB issued ASU
No.
2016
-
01,
Recognition and Measurement of Financial Assets and Financial Liabilities
. The standard is intended to improve the recognition, measurement, presentation and disclosure of financial instruments. This ASU is effective using the modified retrospective approach for annual periods and interim periods within those annual periods beginning after
December 15, 2017,
which for us is
July 1, 2018.
Early adoption is permitted. We do
not
expect the application of this standard to have a significant impact on our result of operations or financial position.
 
In
February, 2016,
the FASB issued ASU
2016
-
02,
Leases (Topic
842
), which amends the existing guidance to require lessees to recognize lease assets and lease liabilities from operating leases on the balance sheet. This ASU is effective using the modified retrospective approach for annual periods and interim periods within those annual periods beginning after
December 15, 2018,
which for us is
July 1, 2019.
Early adoption is permitted. We are currently evaluating the impact of the adoption of ASU
2016
-
02
on our consolidated financial statements.
 
In
March 2016,
the FASB issued ASU
2016
-
09,
Improvements to Employee Share-Based Payment Accounting
. This update includes provisions intended to simplify various aspects related to how share-based payments are accounted for and presented in the financial statements. This ASU is effective for annual periods and interim periods within those annual periods beginning after
December 15, 2016,
which for us is
July 1, 2017.
Early adoption is permitted. Upon adoption, among other impacts, the Company expects its reported provision for income taxes to become more volatile, dependent upon market prices and volume of share-based compensation exercises and vesting of options.
 
In
June 2016,
the FASB issued ASU
2016
-
13,
Financial Instruments - Credit Losses (Topic
326
), Measurement of Credit Losses on Financial Instruments
. The amendments in this update replace the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses. This update is intended to provide financial statement users with more decision-useful information about the expected credit losses. This ASU is effective for annual periods and interim periods within those annual periods beginning after
December 15, 2019,
which for us is
July 1, 2020.
Entities
may
early adopt beginning after
December 15, 2018.
We are currently evaluating the impact of the adoption of ASU
2016
-
13
on our consolidated financial statements.
 
 
In
January 2017,
the FASB issued ASU
No.
2017
-
01,
Clarifying the Definition of a Business
. The standard revises the definition of a business, which affects many areas of accounting such as business combinations and disposals and goodwill impairment. The revised definition of a business will likely result in more acquisitions being accounted for as asset acquisitions, as opposed to business combinations. This ASU is effective for annual periods and interim periods within those annual periods beginning after
December 15, 2018,
which for us is
July 1, 2019
required to be applied prospectively to transactions occurring on or after the effective date.